MedTrace Logo

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

NCT05950516 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 478

Last updated 2023-07-18

No results posted yet for this study

Summary

To evaluate the similarity of the efficacy and safety of semaglutide injection (QLG2065) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.

Conditions

Interventions

DRUG

Semaglutide

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks

DRUG

Semaglutide Pen Injector [Ozempic]

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jiajun Zhao · Shandong Provincial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-10
Primary Completion
2024-11-24
Completion
2025-01-22

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05950516 on ClinicalTrials.gov